Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: john jansen who wrote (597)	11/13/1998 3:23:00 PM
From: Marty	Read Replies (1) \| Respond to of 705

For those with the training to understand them, there are six new summaries of the independent studies that were presented at the Annual Neuroscience Conference. One of the points I was able to understand was that "AIT-082 enhances memory in young adult mice, reverses age-induced memory deficits in old mice and delays the onset of age-induced memory loss." Since the animal tests, NEOT has completed phase 1 human testing and the drug appears to have the same kinds of results in humans. Phase 2 testing is now into the 30-day follow-up stage. The analysis and summaries should be out the first of the year. Here is one fascinating comparison. Neotrofin got statistically significant results with just 18 patients in 90 minutes! In other words, 17 out of 18 patients on Neotrofin had measurable and statistically significant improvement in 90 minutes. It took 150 patients and 90 DAYS to get statistically significant improvement for Aricept, which is one of two Alzheimer drugs now on the open market. Aricept, as I understand it, seems to just slow down the degenerative process. For the rest of us there is also this press release that is more understandable. neotherapeutics.com On top of all that, the allied drugs they have in the same Neotrofin family are so promising for treatment of spinal cord injuries and strokes, etc. that they are going into clinical testing next year. One of the good things is that they can go right into phase 2 for these applications because the phase 1 tests are behind them. I continue to believe that it is going to take time and there will be ups and downs. Nevertheless, the drug has so much potential for really effective treatment and the company will some day be so profitable (Alzheimer's is the fourth leading cause of death now in the US) that I am going to continue to accumulate it.